Close Menu

NEW YORK – Rosa Biotech said Thursday that it has raised £760,000 ($984,000) from angel investors to commercialize an artificial intelligence-based biosensing technology that mimics mammals’ sense of smell with a potential application for medical diagnostics and pharmaceuticals.

University of Bristol, UK-spinout Rosa said that it will use the funding to grow its team, build out an automated platform, and demonstrate the utility of its technology to address challenges in new sectors.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
Thermo Fisher Scientific

With COVID-19 vaccines rolling out, clinical labs and test developers are preparing for changes in both demand for testing and types of testing for SARS-CoV-2.

Sponsored by

Amid the COVID-19 pandemic, hospitals and intensive care units around the world have been overwhelmed by unprecedented levels of demand. 

Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.